Welcome to our dedicated page for Zimmer Biomet Holdings news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet Holdings stock.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) is a preeminent global leader in musculoskeletal healthcare. Headquartered in Warsaw, Indiana, Zimmer Biomet has been at the forefront of advancing bone and joint health for nearly 90 years. The company designs, manufactures, and markets a comprehensive range of orthopedic implants and surgical equipment, addressing joint reconstruction, bone repair, sports medicine, spine, and dental reconstruction. Its innovative product portfolio includes the ROSA® Robotics systems for knee, hip, and shoulder replacements, and the TMINI Miniature Robotic System for total knee arthroplasty.
Zimmer Biomet's latest endeavors include the establishment of a dedicated Health Equity division in 2023, which aims to integrate health equity into the company's core strategies and operations. This division has already made significant strides by assembling a strategic advisory board and developing the Community Centered Care (C3) framework to increase patient access to quality care in underserved communities.
In addition, Zimmer Biomet has recently partnered with top pickleball organizations in the U.S., underscoring its commitment to joint health and well-being for the growing community of pickleball players. The company also announced a strategic alliance with CBRE Group, Inc. to expand orthopedic ambulatory surgery centers across the country, and a collaboration with RevelAi Health to commercialize AI-powered engagement solutions aimed at advancing value-based orthopedic care and health equity.
Financially, Zimmer Biomet has demonstrated robust performance, with first-quarter 2024 net sales amounting to $1.889 billion, a 3.2% year-over-year increase. The company continues to focus on innovation, operational excellence, and strategic partnerships to drive growth and enhance shareholder value. For more information, visit www.zimmerbiomet.com or follow them on LinkedIn and Twitter.
Zimmer Biomet Holdings (NYSE and SIX: ZBH) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team will deliver a presentation on Tuesday, January 14, 2025, at 8:15 a.m. PT (11:15 a.m. ET).
Investors and interested parties can access a live webcast of the presentation through Zimmer Biomet's Investor Relations website. The presentation will also be archived for later viewing following the conference.
Zimmer Biomet Holdings (NYSE and SIX: ZBH) has announced its Board of Directors' approval of a quarterly cash dividend for the fourth quarter of 2024. Shareholders will receive $0.24 per share, with the payment scheduled for January 31, 2025. To be eligible, stockholders must be on record by the close of business on December 30, 2024.
Zimmer Biomet (NYSE: ZBH) has received FDA 510(k) clearance for its OsseoFit™ Stemless Shoulder System for total shoulder replacement. The innovative implant features an anatomically shaped design that matches natural humeral anatomy while preserving healthy bone. The system integrates with Identity® Humeral Heads and Alliance® Glenoid, offering versatile options for patient-specific needs.
Key features include left-or-right-sided anchor implants with fins for press-fit insertion, fully porous windows, and anterior reattachment suture holes. The system comes in a single instrument tray for efficient workflow. Commercial availability is scheduled for Q1 2025.
Zimmer Biomet (NYSE: ZBH) has received FDA 510(k) clearance for its Persona® SoluTion™ PPS® Femur, a total knee implant component designed for patients with sensitivities to bone cement and/or metal. The implant features a porous coating for cementless fixation and a proprietary surface treatment for enhanced wear performance.
The device, when combined with Persona OsseoTi® Tibia and OsseoTi Patella, offers a fully cementless alternative to cobalt-chrome implants. Made of Tivanium® alloy, it minimizes common metal sensitizers and demonstrates similar wear performance compared to traditional cobalt chromium alloy components. Commercial availability in the U.S. is expected in Q1 2025.
Zimmer Biomet has received FDA approval for the Oxford® Cementless Partial Knee, making it the only cementless partial knee replacement implant available in the U.S. The approval is based on safety and effectiveness data from an IDE study. The device offers improved fixation, better long-term implant survival, and enhanced operating room efficiency compared to cemented procedures. With over 20 years of clinical experience and 300,000+ procedures worldwide, the implant features a mobile bearing design that mimics natural knee movement. The UK registry shows a 94.1% implant survival rate at 10 years, surpassing the average for other partial knees. U.S. launch is planned for Q1 2025.
Zimmer Biomet Holdings (NYSE and SIX: ZBH) has announced its participation in the upcoming Citi Global Healthcare Conference. The company's management team will engage in a fireside chat on December 5, 2024, at 8:45 a.m. ET. Investors and interested parties can access a live webcast of the presentation through Zimmer Biomet's Investor Relations website. The presentation will be archived for future viewing after the conference concludes.
Zimmer Biomet (NYSE: ZBH) has received CE Mark certification for its Persona® Revision Knee System, expanding its availability in European markets. The system, which leads the $700+ million U.S. knee revision market, offers personalized solutions for revision knee arthroplasty. It features Trabecular Metal™ Technology for improved implant fixation and bone in-growth, along with modular components that enable surgeons to address complex cases with greater precision. The system's anatomic components and instrumentation are designed to streamline revision surgery while allowing intraoperative adjustments for optimal alignment and fit.
Zimmer Biomet (NYSE: ZBH) has announced a partnership with Arnold Schwarzenegger as their new Chief Movement Officer. In this strategic role, Schwarzenegger will work to motivate and support individuals in increasing mobility, maintaining joint health, and incorporating movement into daily routines. The partnership aligns with Zimmer Biomet's mission as a MedTech leader to alleviate pain and improve quality of life worldwide. Schwarzenegger, known for his 50-year fitness advocacy through various platforms including the Arnold Sports Festival and 'Arnold's Pump Club' newsletter, will collaborate with the company to promote active living and wellness initiatives.
Zimmer Biomet (NYSE and SIX: ZBH) has announced its participation in the upcoming Jefferies London Healthcare Conference. The company's management team will engage in a fireside chat on November 19, 2024, at 11:00 a.m. GMT (6:00 a.m. ET). Investors and interested parties can access a live webcast of the presentation through Zimmer Biomet's Investor Relations website. The presentation will be available for replay after the conference.
Zimmer Biomet (NYSE: ZBH) reported Q3 2024 financial results with net sales of $1.824 billion, representing a 4.0% increase year-over-year. The company achieved net earnings of $249.1 million, with diluted EPS of $1.23 and adjusted diluted EPS of $1.74. Notable developments include the planned launch of the Z1™ Femoral Hip System and acquisition of OrthoGrid Systems. However, due to ERP implementation challenges, the company has updated its 2024 guidance, reducing full-year revenue growth expectations to 3.5-4.0% from previous 4.0-5.0%, and narrowing adjusted EPS guidance to $7.95-$8.05 from $8.00-$8.15.
FAQ
What is the current stock price of Zimmer Biomet Holdings (ZBH)?
What is the market cap of Zimmer Biomet Holdings (ZBH)?
What does Zimmer Biomet do?
Where is Zimmer Biomet headquartered?
What are Zimmer Biomet's latest innovations?
What is Zimmer Biomet's focus on health equity?
How did Zimmer Biomet perform financially in the first quarter of 2024?
What are Zimmer Biomet's partnerships?
What is the ROSA® Robotics system?
What is the Community Centered Care (C3) framework?
What is Zimmer Biomet's role in pickleball?
How does Zimmer Biomet contribute to innovation in healthcare?
